U.S. Food and Drug Administration Clears Sickle Cell Disease Indication with New Red Blood Cell Exchange (RBCX) Protocol on the Spectra Optia® Apheresis System in the United States
December 16, 2013 at 14:00 PM EST
LAKEWOOD, Colo.---- Terumo BCT has received 510 clearance from the U.S. Food and Drug Administration for RBCX on the Spectra Optia Apheresis System.